Rubius Therapeutics, Inc. (RUBY) News & Overview - Discounting Cash Flows
RUBY
Rubius Therapeutics, Inc.
RUBY (NASDAQ)

RUBY's Business Model

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Sector & Industry Healthcare / Biotechnology
Website https://www.rubiustx.com
CEO (Chief Executive Officer) Laurence A. Turka
Number of Employees
IPO date July 18, 2018

RUBY Latest News

Contact
CountryUS
Address399 Binney Street
CityCambridge
StateMA
Phone617 679 9600
Zip Code02139
Other Identifiers
CIK0001709401
ISINUS78116T1034
CUSIP78116T103
Open0.0555
Previous Close0.0555
Volume755.9 Thou.
Average Volume99.53 Thou.
Day’s Range0.055 – 0.057
52 Week Range0.0032-0.3763
MA (50)0.021742
MA (200)0.01987485
Market Cap0
Shares Out.0
Earnings DateFeb 26, 2024
Beta
Last Dividend
EPS
PE

Industry Competitors for RUBY

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us